You are here

Study Evaluating EKB-569 in Advanced Colorectal Cancer

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Signed and dated, institutional review board (IRB) or independent ethics committee
(IEC)-approved informed consent form before any protocol-specific screening procedures

- Previous histologic diagnosis of adenocarcinoma of the colon or rectum

- EGFR expression by immunohistochemical analysis (must be > or = 20% positive tumor
cells in prior tumor biopsy specimens)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Chemotherapy, radiotherapy, anticancer immunotherapy, or investigational agents within
4 weeks of treatment day 1 (6 weeks if the previous regimen included mitomycin or
nitrosoureas).

- Prior epidermal growth factor receptor-targeting therapy

- Known central nervous system (CNS) metastases

NCT00072748
Pfizer
Completed
Study Evaluating EKB-569 in Advanced Colorectal Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now